Search Results - "Quon, Doris V"

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A by Konkle, Barbara A, Shapiro, Amy D, Quon, Doris V, Staber, Janice M, Kulkarni, Roshni, Ragni, Margaret V, Chhabra, Ekta S, Poloskey, Stacey, Rice, Kara, Katragadda, Suresh, Fruebis, Joachim, Benson, Craig C

“…In a study involving patients with severe hemophilia A, an injection of the novel fusion protein BIVV001 resulted in a duration of factor VIII activity that…”
Get full text

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A by Madan, Bella, Ozelo, Margareth C., Raheja, Priyanka, Symington, Emily, Quon, Doris V., Leavitt, Andrew D., Pipe, Steven W., Lowe, Gillian, Kenet, Gili, Reding, Mark T., Mason, Jane, Wang, Michael, von Drygalski, Annette, Klamroth, Robert, Shapiro, Susan, Chambost, Hervé, Dunn, Amy L., Oldenburg, Johannes, Chou, Sheng-Chieh, Peyvandi, Flora, Millar, Carolyn M., Osmond, Dane, Yu, Hua, Dashiell-Aje, Ebony, Robinson, Tara M., Mahlangu, Johnny

“…Valoctocogene roxaparvovec transfers a human factor (F)VIII coding sequence into hepatocytes of people with severe hemophilia A to provide bleeding protection…”
Get full text

Prevalence and Risk Factors for Hypertension in Hemophilia by von Drygalski, Annette, Kolaitis, Nicholas A, Bettencourt, Ricki, Bergstrom, Jaclyn, Kruse-Jarres, R, Quon, Doris V, Wassel, Christina, Li, Ming C, Waalen, Jill, Elias, Darlene J, Mosnier, Laurent O, Allison, Matthew

“…Hypertension (HTN) is a major risk factor for intracranial hemorrhage. We, therefore, investigated the prevalence, treatment, and control of HTN in adult…”
Get full text

Consistency of serial ultrasonographic joint tissue measurements by the Joint tissueActivity and Damage Exam (JADE) protocol in relation to hemophilic joint health parameters by Barnes, Richard F. W, Aguero, Peter, Hanacek, Cris, Flores, Andres, Steiner, Bruno, Bailey, Cindy, Quon, Doris V, Kruse-Jarres, Rebecca, von Drygalski, Annette

“…Abstract Objectives The Joint tissue Activity and Damage Exam (JADE) is a point-of-care (POC) musculoskeletal ultrasound (MSKUS) protocol for non-radiologists…”
Get full text

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A by Ozelo, Margareth C, Mahlangu, Johnny, Pasi, K. John, Giermasz, Adam, Leavitt, Andrew D, Laffan, Michael, Symington, Emily, Quon, Doris V, Wang, Jiaan-Der, Peerlinck, Kathelijne, Pipe, Steven W, Madan, Bella, Key, Nigel S, Pierce, Glenn F, O’Mahony, Brian, Kaczmarek, Radoslaw, Henshaw, Joshua, Lawal, Adebayo, Jayaram, Kala, Huang, Mei, Yang, Xinqun, Wong, Wing Y, Kim, Benjamin

“…Patients with severe hemophilia A were treated with an adenoviral construct containing coagulation factor VIII cDNA and followed for 1 to 3 years. Median…”
Get full text

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A by Mahlangu, Johnny, Kaczmarek, Radoslaw, von Drygalski, Annette, Shapiro, Susan, Chou, Sheng-Chieh, Ozelo, Margareth C., Kenet, Gili, Peyvandi, Flora, Wang, Michael, Madan, Bella, Key, Nigel S., Laffan, Michael, Dunn, Amy L., Mason, Jane, Quon, Doris V., Symington, Emily, Leavitt, Andrew D., Oldenburg, Johannes, Chambost, Hervé, Reding, Mark T., Jayaram, Kala, Yu, Hua, Mahajan, Reena, Chavele, Konstantia-Maria, Reddy, Divya B., Henshaw, Joshua, Robinson, Tara M., Wong, Wing Yen, Pipe, Steven W.

“…Participants with hemophilia A received B-domain–deleted factor VIII gene therapy delivered in an AAV5 vector. A decrease in annualized bleeding rates was…”
Get full text

The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study by Quon, Doris V. K., Kruse-Jarres, Rebecca, Sait, Afrah S., Cramer, Thomas J., Barnes, Richard F. W., von Drygalski, A.

“…Background. The etiology of the high prevalence of hypertension among patients with hemophilia (PWH) remains unknown. Methods. We compared 469 PWH in the…”
Get full text

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A by Klamroth, Robert, Hayes, Gregory, Andreeva, Tatiana, Gregg, Keith, Suzuki, Takashi, Mitha, Ismail Haroon, Hardesty, Brandon, Shima, Midori, Pollock, Toni, Slev, Patricia, Oldenburg, Johannes, Ozelo, Margareth C, Stieltjes, Natalie, Castet, Sabine-Marie, Mahlangu, Johnny, Peyvandi, Flora, Kazmi, Rashid, Schved, Jean-François, Leavitt, Andrew D, Callaghan, Michael, Pan-Petesch, Brigitte, Quon, Doris V, Andrews, Jayson, Trinh, Alex, Li, Mingjin, Wong, Wing Yen

“…Adeno-associated virus (AAV)-mediated gene therapy may provide durable protection from bleeding events and reduce treatment burden for people with hemophilia A…”
Get more information

Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B by O’Connell, Niamh, van der Valk, Paul, Le Quellec, Sandra, Gomez, Esteban, Monahan, Paul E., Crary, Shelley E., Coppens, Michiel, Lemons, Richard, Castaman, Giancarlo, Klamroth, Robert, Symington, Emily, Quon, Doris V., Kampmann, Peter

“…Little information regarding the management of invasive procedures in people with hemophilia B (HB) after undergoing gene therapy is available. Here, we report…”
Get full text

Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years by Shapiro, Amy, Chaudhury, Ateefa, Wang, Michael, Escobar, Miguel, Tsao, Elisa, Barnowski, Christopher, Feng, Jing, Jain, Nisha, Quon, Doris V.

“…Introduction In clinical trials, recombinant factor IX fusion protein (rFIXFc) has demonstrated safety, efficacy and prolonged activity with extended dosing…”
Get full text

Risk of diabetes in haemophilia patients compared to clinic and non‐clinic control cohorts by Pandey, Braj, Barnes, Richard F.W., Sun, Haowei (Linda), Jackson, Shannon, Kruse‐Jarres, Rebecca, Quon, Doris V., von Drygalski, Annette

“…Introduction Ageing patients with haemophilia (PWH) develop cardiovascular risk factors impacting care. Little is known about the prevalence of diabetes in PWH…”
Get full text

Development and Reliability of the Joint Tissue Activity and Damage Examination for Quantitation of Structural Abnormalities by Musculoskeletal Ultrasound in Hemophilic Joints by Volland, Lena M., Zhou, Jenny Y., Barnes, Richard F. W., Kruse‐Jarres, Rebecca, Steiner, Bruno, Quon, Doris V., Bailey, Cindy, Hughes, Tudor H., Moore, Randy E., Chang, Eric Y., von Drygalski, Annette

“…Objectives Musculoskeletal ultrasound (US) is used increasingly to examine hemophilic arthropathy. However, quantitative algorithms to document findings are…”
Get full text

Blood pressure in persons with haemophilia with a focus on haemophilia‐specific risk factors by Ter‐Zakarian, Anna, Barnes, Richard F. W., Kruse‐Jarres, Rebecca, Quon, Doris V., Jackson, Shannon, Sun, Haowei (Linda), Drygalski, Annette

“…Introduction Persons with haemophilia (PWH) have a higher prevalence of hypertension compared to the general population, which cannot be explained entirely by…”
Get full text

Diabetes, hepatitis C and human immunodeficiency virus influence hypertension risk differently in cohorts of haemophilia patients, veterans and the general population by Barnes, Richard F.W., Pandey, Braj, Sun, Haowei (Linda), Jackson, Shannon, Kruse‐Jarres, Rebecca, Quon, Doris V., Drygalski, Annette

“…Introduction The reasons for the high prevalence of hypertension in persons with haemophilia (PWH) are poorly understood. Aim To examine the roles of diabetes,…”
Get full text

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports by Wang, Michael, Álvarez-Román, María Teresa, Chowdary, Pratima, Quon, Doris V, Schafer, Kim

“…The World Federation of Hemophilia and the National Hemophilia Foundation encourage people with haemophilia (PWH) to participate in routine physical activity…”
Get full text

A Dynamin Is Required for the Biogenesis of Secretory Organelles in Toxoplasma gondii by Breinich, Manuela S., Ferguson, David J.P., Foth, Bernardo J., van Dooren, Giel G., Lebrun, Maryse, Quon, Doris V., Striepen, Boris, Bradley, Peter J., Frischknecht, Friedrich, Carruthers, Vern B., Meissner, Markus

“…Apicomplexans contain only a core set of factors involved in vesicular traffic. Yet these obligate intracellular parasites evolved a set of unique secretory…”
Get full text

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia by Tran, Duc Q, Benson, Craig C, Boice, Judith A, Chitlur, Meera, Dunn, Amy L, Escobar, Miguel A, Gupta, Kalpna, Johnsen, Jill M, Jorgenson, James, Martin, Scott D, Martin, Suzanne, Meeks, Shannon L, Narvaez, Jr, Alfredo A, Quon, Doris V, Reding, Mark T, Reiss, Ulrike M, Savage, Brittany, Schafer, Kim, Steiner, Bruno, Thornburg, Courtney, Volland, Lena M, von Drygalski, Annette

“…Decades of research have transformed hemophilia from severely limiting children's lives to a manageable disorder compatible with a full, active life, for many…”
Get more information

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma by Chawla, Sant P., Chua, Victoria S., Hendifar, Andrew F., Quon, Doris V., Soman, Neelesh, Sankhala, Kamalesh K., Wieland, D. Scott, Levitt, Daniel J.

“…BACKGROUND Aldoxorubicin, a prodrug of doxorubicin, covalently binds to serum albumin, allowing for the administration of much higher doses of doxorubicin in a…”
Get full text

Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial by Coppens, Michiel, Pipe, Steven W, Miesbach, Wolfgang, Astermark, Jan, Recht, Michael, van der Valk, Paul, Ewenstein, Bruce, Pinachyan, Karen, Galante, Nicholas, Le Quellec, Sandra, Monahan, Paul E, Leebeek, Frank W G, Castaman, Giancarlo, Crary, Shelley E, Escobar, Miguel, Gomez, Esteban, Haley, Kristina M, Hermans, Cedric R J R, Kampmann, Peter, Kazmi, Rashid, Key, Nigel S, Klamroth, Robert, Konkle, Barbara A, Kruse-Jarres, Rebecca, Lattimore, Susan, Lemons, Richard, Meijer, Karina, O'Connell, Niamh, Quon, Doris V, Raheja, Priyanka, Symington, Emily, Verhamme, Peter, Visweshwar, Nathan, von Drygalski, Annette, Wang, Michael, Wheeler, Allison P, White, Shanna, Young, Guy

“…Etranacogene dezaparvovec, the first gene therapy approved for haemophilia B treatment, was shown to be superior to treatment with continuous prophylactic…”
Get full text

A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE) by Konkle, Barbara A, Quon, Doris V, Raffini, Leslie, Recht, Michael, Radulescu, Vlad C, Carpenter, Shannon L, Dunn, Amy L, Lu, Mei, Watt, Maureen

“…High collision-risk physical activity can increase bleeding risk in people with hemophilia A, as can increasing the time between factor VIII (FVIII)…”
Get full text